Natera, Inc.
NTRA
주식 순위
#426
Natera, Inc. is a diagnostics company focused on developing and commercializing... Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
주가
$392.17
마지막 동기화: 2026-10-16
시가총액
$56.53B
변동 (1일)
-3.12%
변동 (1년)
115.84%
국가
US
거래 Natera, Inc. (NTRA)
카테고리
Healthcare
Natera, Inc. (NTRA)의 영업이익률
October 2026 기준 영업이익률 TTM: -10.70%
Natera, Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 -10.70%입니다. 2023년 말 기준 영업이익률은 -41.22%였습니다.
Natera, Inc.의 영업이익률 기록 (2012 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | -10.70% | -18.32% |
| 2024 | -13.10% | -68.22% |
| 2023 | -41.22% | -37.51% |
| 2022 | -65.96% | -11.88% |
| 2021 | -74.85% | 35.33% |
| 2020 | -55.31% | 43.81% |
| 2019 | -38.46% | -13.55% |
| 2018 | -44.49% | -29.98% |
| 2017 | -63.54% | 42.95% |
| 2016 | -44.45% | 41.43% |
| 2015 | -31.43% | -7,583.33% |
| 2014 | 0.42% | -100.92% |
| 2013 | -45.80% | -66.03% |
| 2012 | -134.84% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 17.97% | -101.68% |
US
|
|
| 20.42% | -101.91% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -102.08% |
US
|
|
| 32.03% | -102.99% |
US
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.